Toxicity
Modern estimates of toxicity are taken from a recent randomised, open-label, phase III study. From April 2003 to January 2005, a total of 316 patients with advanced gastric cancer were enrolled to receive cisplatin (80 mg/m2 day 1) plus capecitabine (1000 mg/m2 BD d1 to 14) (XP) or cisplatin (80 mg/m2 day 1) plus 5FU (800 mg/m2/day by continuous infusion, d1 to 5) (FP) every 3 weeks. The primary end-point was to confirm noninferiority of XP versus FP for progression-free survival (PFS).r
The most common treatment-related grade 3/4 adverse events in FP patients were as follows: neutropenia (19%), vomiting (8%), and stomatitis (6%).r
Toxicityr
© Annals of Oncology 2009